Drugs / TDV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02948829 | Apr → Oct 2017 | — | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02948829 ↗ |
| Modality | Vaccine | “The vaccine tested in this study was TDV.” NCT02948829 ↗ |
| Route | Subcutaneous | “TDV 0.5 mL subcutaneous (SC) injection into the upper arm at Day 1 (Month 0) and at Day 90 (Month 3).” NCT02948829 ↗ |